UK markets close in 1 hour 12 minutes

Tiziana Life Sciences PLC (TIZAF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.85000.0000 (0.00%)
As of 9:33AM EDT. Market open.

Tiziana Life Sciences PLC

107 Cheapside
9th Floor
London EC2V 6DN
United Kingdom
44 20 7495 2379
http://www.tizianalifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees11

Key executives

NameTitlePayExercisedYear born
Mr. Gabriele Marco Antonio Cerrone M.B.A., MBAFounder & Exec. Chairman13.76MN/A1972
Dr. Kunwar ShailubhaiCEO, Chief Scientific Officer & Exec. Director810kN/A1958
Dr. Andrea BrancaleScientific FounderN/AN/AN/A
Mr. Richard Clarkson Ph.D.Scientific FounderN/AN/AN/A
Mr. Andrew Westwell Ph.D.Scientific FounderN/AN/AN/A
Ms. Keeren ShahFin. DirectorN/AN/A1977
Dr. Thomas H. Adams Ph.D.Head of Drug Devel. & Exec. DirectorN/AN/A1943
Dr. Neil Graham M.D., M.P.H., MBBS, MPHChief Medical OfficerN/AN/A1959
Dr. Napoleone FerraraChairman of Scientific Advisory BoardN/AN/A1958
Prof. Roberto PellicciariConsultantN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.

Corporate governance

Tiziana Life Sciences PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.